



This document was valid from 13 July 2006 until February 2016. It is now superseded by a [new version](#) adopted by the HMPC on 2 February 2016 and published on the EMA website.

LIST OF REFERENCES SUPPORTING THE ASSESSMENT REPORT ON:

Valeriana officinalis L., radix
(EMEA/HMPC/167391/2006)

The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

1. Ad hoc working group on herbal medicinal products of the EMEA Final Proposal for a core-data for Valerianae radix (EMEA/HMPWG/14/99) September 1998
2. Albrecht M, Berger W, Laux P, Schmidt U, et al.: Psychopharmaka und Verkehrssicherheit. Der Einfluß von Euvegal[®] - Dragees forte auf die Fahrtüchtigkeit und Kombinationswirkungen mit Alkohol. Z. Allg. Med. 1995; 71: 1215-25
3. Angst J, Borebely A, Engel RR, et al.: Report on the sixth consensus conference on the methodology of clinical trials with hypnotic drugs. Pharmacopsychiat 1995; 28: 2-7
4. Balderer G, Borbely AA: Effect of valerian on human sleep. Psychopharmacol 1985; 87: 406-9
5. Balduini W, Cattabeni F: Displacement of [³H] N⁶-cyclohexyladenosine binding to rat cortical membranes by an hydroalcoholic extract of *Valeriana officinalis*. Med. Sci Res. 1989; 17: 639-40
6. Bodesheim U, Hölzl J: Isolierung, Strukturaufklärung und Radiorezeptorassay von Alkaloiden und Lignanen aus *Valeriana officinalis* L. Pharmazie 1997; 52: 386-91
7. Bos R, Woerdenbag HJ, De Smet PAGM, et al.: Valeriana Species. In: DeSmet PGMA, Keller K, Haensel R, Chandler RD (eds): Adverse Effects of Herbal Drugs. Vol 3, Springer-Verlag Berlin, 1998; 165-80
8. Cavadas C, Araújo I, Cotrim MD, Amaral T, Cunha AP, Macedo T, Fontes Ribeiro C: *In vitro* Study on the Interaction of *Valeriana officinalis* L. Extracts and Their Amino Acids on GABA-A Receptor in Rat Brain. Arzneim.-Forsch./Drug Res. 1995; 45(II) No 7: 753-5
9. Coxeter PD, Schluter PJ, Eastwood HL, et al.: Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complementary Therapies in Medicine 2003; 11: 215-22
10. Cropley M, Cave Z, Ellis J, Middleton RW: Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytotherapy Research 2002; 16: 23-7
11. Diaper A, Hindmarch I: A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytotherapy Res 2004; 18: 831-6
12. Donath F; Quispe S; Diefenbach K; et al.: Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsych 2000; 33: 47-53

13. Donovan JL, DeVane CL, Chavin KD, et al.: Multiple night time doses of valerian (*Valeriana officinalis*) had minimal effects on CYP 3A4 activity and no effect on CYP 2D6 activity in healthy volunteers. *Drug Metab Dispos* 2004
14. Dorn M: Efficacy and tolerability of valerian versus oxazepam in non-organic and non-psychiatric insomnias: a randomized, double-blind, clinical, comparative study. *Komplementaermedizin und Klassische Naturheilkunde* 2000; 7: 79-84
15. ESCOP Monograph: *Valerianae radix*. European Scientific Cooperative on Phytomedicine, July 1997
16. Fehri B, Aiache JM, Boukef K, Memmi A, Hizaoui B: *Valeriana officinalis* et *Crataegus oxyacantha*: Toxicité par administrations réitérées et investigations pharmacologiques. *J. Pharm. Belg.* 1991; 46/3: 165-76
17. Feldmeier Ch, Kapp W: Comparative clinical studies with midazolam, oxazepam and placebo. *Br J Clin Pharmacol* 1983; 16, 151S-155S
18. Fernández S, Wasowski C, Paladini AC, marder M: Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from *Valeriana officinalis*. *Pharm Biochem Behav* 2004; 77: 399-404
19. Ferreira F, Santos MS, Faro C, et al.: Effect of extracts of *Valeriana officinalis* on [³H]GABA. *Rev Port Farm* 1996; 46: 74-7
20. Garges HP, Varia I, Doraiswamy PM: Cardiac complications and delirium associated with valerian root withdrawal. *JAMA* 1998; 280: 1566-7
21. Gerhard U, Linnenbrink N, Georghiadou C, Hobi V: Vigilanzmindernde Effekte zweier pflanzlicher Schlafmittel. *Schweiz. Rundsch. Med. (Praxis)* 85 1996; 15: 473-81
22. Goldstein SE, et al.: Comparison of oxazepam, flurazepam and chloral hydrate as hypnotic sedatives in geriatric patients. *J Am Geriatr Soc* 1978, 26: 366-71
23. Gurley BJ, Gardner SF, Hubbard MA, et al.: In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1a^α; „D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Therapeutics* 2005; 415-26
24. Gutierrez S, Ang-Lee MK, Walker D, Zacny JP: Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. *Pharmacol Biochem Behav* 2004; 78: 57-64
25. Hallam KT, Olver JS, McGrath C, Norman TR: Comparative cognitive and psychomotor effects of single doses of *Valeriana officinalis* and triazolam in healthy volunteers. *Human Psychopharmacology* 2003; 18: 619-25
26. Hänsel R, Keller K, Rimpler H, Schneider G (eds): *Hagers Handbuch der Pharmazeutischen Praxis*. Monograph: *Valeriana*. Vol. 6: Drogen P-Z, 5th ed. Springer publishers, Berlin Heidelberg New York. 1994: 1067-95
27. Hänsel R, Sticher O, Steinegger G (eds.). *Pharmakognosie - Phytopharmazie*, Springer Verlag Berlin Heidelberg New York 1999
28. Hazelhoff B, Malingré TH M, Meijer DKF: Antispasmodic Effects of *Valeriana* Compounds. An in-Vivo and in-Vitro Study on the Guinea-Pig Ileum. *Arch. Int. Pharmacodyn.* 1982; 257: 274-87
29. Hendriks H, Bos R, Allersma DP, Malingré Th M, Koster AS: Pharmacological screening of valeranal and some other components of essential oil of *Valeriana officinalis*. *Planta Medica* 1981; 42: 62-8
30. Hendriks H, Bos R, Woerdenbag HJ, Koster AS: Central nervous depressant activity of valerenic acid in the mouse. *Planta Med.* 1985; 51: 28-31

31. Herberg KW: Doppelblinde Crossoverstudie zum Einfluß einer Hopfen-Baldrian-Kombination (Ivel[®]) und von Placebo allein und in Kombination mit Alkohol auf Verkehrssicherheit und allgemeine Leistungsfähigkeit von Probanden (Study No. MI 9218). TÜV Rheinland, Köln, April 1994 (a)
32. Herberg KW: Psychotrope Phytopharmaka im Test: Alternative zu synthetischen Psychopharmaka? Therapiewoche 1994; 44 (12): 704-13
33. Hiller K-O, Kato G: Anxiolytic Activity of Psychotropic Plant Extracts. I. Test of Ethanolic *Valeriana* Extract STEI Val. 44th Annual Congress of the Society for Medical Plant Research, Prague 1996, Poster P 65
34. Hiller K-O, Zetler G: Neuropharmacological Studies on Ethanol Extracts of *Valeriana officinalis* L.: Behavioral and Anticonvulsant Properties. Phytotherapy Research. 1996; 10: 145-51
35. Hintelmann C: Sleep disorders in children: observational study with a high dosage valerian extract. Schweiz Z Ganzheits medizin 2002; 14: 404-7
36. Holm E, Kowollik H, Reinecke A, Henning v. GE, Behne F, Scherer H-D: Vergleichende neurophysiologische Untersuchungen mit Valtratum/Isovaltratum und Extractum Valerianae an Katzen. Med. Welt. 1980; 31 (26): 982-90
37. Houghton PJ: The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999 May; 51(5): 505-12
38. Jacobs BP, Bent S, Tice JA, et al.: An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine 2005; 84: 197-207
39. Kammerer E, Brattström A, Herberg KW: Einfluß einer Hopfen-Baldrian-Kombination auf Leistungsfähigkeit und Verkehrssicherheit. Der Bayerische Internist 1996; 16: 32-6
40. Kamm-Kohl AV, Jansen W, Brockmann P: Moderne Baldriantherapie gegen nervöse Störungen im Senium. Med. Welt 1984; 35: 1450-4
41. Kohnen R, Oswald W-D: The effects of valerian, propranolol, and their combination on activation, performance and mood on healthy volunteers under social stress conditions. Pharmacopsychiat. 1988; 21: 447-8
42. Kuhlmann J, Berger W, Prodzoweit H, et al.: The influence of valerian treatment on „reaction time, alertness and concentration“ in volunteers. Pharmacopsychiat 1999; 32: 235-41
43. Leathwood PD, Chauffard F, Heck E, Munoz-Box R: Aqueous extract of valerian Root (*Valeriana officinalis* L.) improves sleep quality in man. Pharmacol. Biochem. Behav. 1982; 17: 65-71
44. Leathwood PD, Chauffard F: Aqueous extract of valerian reduces latency to fall asleep in man *Planta Medica* 1985; 51: 144-8
45. Leathwood PD, Chauffard F: Quantifying the effects of mild sedatives. J. Psychiatr. Res. 1982/83; 17 (2): 115-22
46. Lefebvre T, Foster BC: In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharmaceut Sci 2004; 7: 265-73
47. Leuschner J, Müller J, Rudmann M: Characterisation of the central nervous depressant activity of a commercially available valerian root extract. *Arzneim.-Forsch./Drug Res.* 1993; 43(1) Nr. 6: 638-41
48. Marder M, Viola H, Wasowski C, et al.: 5-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. *Pharm Biochem Behav* 2003; 75: 537-45
49. Mennini T, Bernasconi P, Bombardelli E, Morazzoni P: *In vitro* study on the interactions of extracts and pure compounds from *Valeriana officinalis* roots with GABA, benzodiazepine and barbiturate receptors in rat brain. *Fitoterapia.* 1993; 64/4: 291-300

50. Mueller CE, Schumacher B, Brattstroem A, et al.: Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. *Life Sciences* 2002; 71: 1939-49
51. Ortiz JG; Nieves-Natal J; Chavez P: Effects of *Valeriana officinalis* extracts on [3H]flunitrazepam binding, Synaptosomal [3H]GABA Uptake, and Hippocampal [3H]GABA Release. *Neurochem Res* 1999; 24: 1373-8
52. Riedel E, Hänsel R, Ehrke G: Inhibition of γ -Aminobutyric Acid by Valerenic Acid Derivatives. *Planta Med.* 1982; 46: 219-20
53. Rosecrans JA, Defeo JJ, Youngken HW Jr: Pharmacological investigation of certain *Valeriana officinalis* L. extracts. *J Pharm Sci.* 1961; 50: 240-4
54. Rücker G, Tautges J, Sieck A, Wenzl H, Graf E: Untersuchungen zur Isolierung und pharmakodynamischen Aktivität des Sesquiterpens Valeranon aus *Nardostachys jatamansi* DC. *Arzneim.-Forsch./Drug Res.* 1978; 28 (I) No. 1: 7-13
55. Santos a Maria S et al: An aqueous extract of valerian influences the transport of GABA in synaptosomes. *Planta Med.* 1994; 60: 278-9
56. Santos b Maria S et al: The amount of GABA present in aqueous extracts of valerian is sufficient to account for [³H]-GABA release in synaptosomes. *Planta Med.* 1994; 60: 475-476
57. Santos c MS, Ferreira F, Cunha AP, Carvalho AP, Ribeiro CF, Macedo T: Synaptosomal GABA release as influenced by valerian root extract-involvement of the GABA carrier. *Arch Int Pharmacodyn Ther* 1994 Mar-Apr; 327(2): 220-31
58. Schulz H, Jobert M: Die Darstellung sedierender/tranquilisierender Wirkungen von Phytopharmaka im quantifizierten EEG. *Z. Phytotherapie*, 6. Phytotherapiekongreß, Berlin 1995; Abstractband: 10
59. Schulz H, Stolz C, Mueller J: The effect of valerian extract on sleep polygraphy in poor sleepers: A pilot study. *Pharmacopsychiat.* 1994; 27: 147-51
60. Schulz H; Jobert M; Huebner WD: The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. *Phytomedicine* 1998; 5: 449-58
61. Schumacher B, Scholle S, Hoelzl J, et al.: Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A₁ receptors. *J Nat Prod* 2002; 65: 1479-85
62. Torrent MT, Iglesias J, Adzet T: Valoración experimental de la actividad sedante de la tintura de *Valeriana officinalis* L. *Circular Farmacéutica.* 1972; 30: 107-12
63. von der Hude W; Scheutwinkel-Reich M; Braun R: Bacterial mutagenicity of the tranquilizing constituents of Valerianaceae roots. *Mutat.Res.* 1986; 169: 23-7
64. Von Skramlik E: Über die Giftigkeit und Verträglichkeit von ätherischen Ölen. *Pharmazie* 1959; 14: 435-45
65. Vorbach EU, Goertelmeyer R, Brüning J: Therapie von Insomnien. Wirksamkeit und Verträglichkeit eines Baldrianpräparates. *Psychopharmakotherapie* 1996; 3: 109-15
66. Wagner H, Jurcic K: *In vitro*- and *in vivo*-Metabolism of ¹⁴C-Didrovaltrate. *Planta Med.* 1980; 38: 366-76
67. Wasowski C, Marder M, Viola H, et al.: Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA_A receptors, from *Valeriana wallichii*. *Planta Med.* 2002; 68: 934-6
68. WHO monographs on selected medicinal plants: *Radix Valeriana*. Volume 1 World Health Organization, Geneva 1999
69. Wiener SW, Hoffmann RS, Nelson LS: Withdrawal symptoms after valerian cessation. *Clin Tox* 2003; 41: 721

70. Willey LB, Mady SP, Cobaugh DJ, et al.: Valerian overdose: a case report. *Vet Human Toxicol* 1995; 37: 364-5
71. Yuan CH, Mehendale S, Yiao Y, et al.: The gamma-aminobutyric acidergic effects of valerian and valeronic acid on rat brainstem neuronal activity. *Anesth Analg* 2004; 98: 353-8
72. Ziegler G, Ploch, Miettinen-Baumann A, Collet W: Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia – a randomized, double-blind, comparative clinical study. *Eur J Med Res* 2002; 7: 480-6
73. Benedum J, Loew D, Schilcher H: *Arzneipflanzen in der traditionellen Medizin. Kooperation Phytopharmaka.*
74. Berendes J: *Des Pedanios Dioskurides aus Anazarbos Arzneimittellehre in fuenf Buechern, Stuttgart 1902*
75. *British Herbal Pharmacopoeia, 1976*
76. Chamisso, A. von: *Illustriertes Heil-,Gift- und Nutzpflanzenbuch.* Ed. Schneebeil-Graf R, Berlin 1987
77. *Culbreth DMR: A manual of materia medica and pharmacology comprising the organic drugs which are or have been recognized by the United States Pharmacopoeia and national formulary. Philadelphia 1927.* Ed. Michael Moore, Southwest School of Botanical Medicine.
78. *Deutsches Arzneibuch 6. Ausgabe 1926, Berlin 1926*
79. Dragendorff G: *Die Heilpflanzen der verschiedenen Voelker und Zeiten.* Stuttgart 1898
80. Haffner Schultz Schmid Braun: *Normdosen gebraeuchlicher Arzneistoffe und Drogen.* 8. Auflage ed. R Braun, Stuttgart 1991
81. Hager H: *Commentar zur Pharmacopoeia Germanica.* , Baende, Berlin 1874/74
82. *Hagers Handbuch der Pharmazeutischen Praxis.* Eds List PH, Hoerhammer L, Berlin 1979
83. Madaus G: *Lehrbuch der biologischen Heilmittel.* 1938, Georg Thieme Verlag Leipzig
84. French Competent Authority: *Notice to manufacturers concerning marketing authorization applications for plant-based medicinal products.* 1990 (non official translation)
85. Usmanghani Kh, et al.: *Indusynic medicine. Traditional medicine of herbal, animal and mineral origin in Pakistan.* Karachi, 1997
86. Martindale W: *Extra Pharmacopoeia, 25th edition, 1967*
87. Sayre LE: *A manual of organic materia medica and pharmacognosy.* 4th edition, Philadelphia 1917
88. Viétz FB: *Icones plantarum medico-oeconomico-technologicarum, Vol I/II.* Wien 1800
89. Ward H: *Herbal manual.* London 1936
90. Weiss RF: *Lehrbuch der Phytotherapie.* Stuttgart, 1944
91. Hölzl J: *Baldrianwurzel.* *Z. Phytotherapie* 1998; 19: 47-54
92. Müller SF, Klement S. *A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children.* *Phytomedicine* 2006; DOI:10.1016/j.phymed.2006.01.013 (article in press)
93. Glass JR et al. *Acute pharmacological effects of temazepam, diphenhydramine and valerian in healthy elderly subjects* *J Clin Psychopharmacol* 2003; 23:260-8 #
94. Romero-Jiménez M. et al. *Genotoxicity and anti-genotoxicity of some traditional herbs.* *Mutat. Res.* 2005; 585: 147-55
95. Stevinson C, Ernst E. *Valerian for insomnia: a systematic review of randomized clinical trials.* *Sleep Med.* 2000; 1(2): 91-9

96. Al-Majed AA, Al-Yahya AA, Al-Bekairi AM et al. Studies on the cytological and biochemical effects of valerian in somatic and germ cells of Swiss albino mice. *Food and Chemical Toxicology* 2006; 44: 1830-7

Superseded